Generic Atripla Availability
Last updated on Dec 12, 2024.
Atripla is a brand name of efavirenz/emtricitabine/tenofovir disoproxil, approved by the FDA in the following formulation(s):
ATRIPLA (efavirenz; emtricitabine; tenofovir disoproxil fumarate - tablet;oral)
-
Manufacturer: GILEAD SCIENCES
Approval date: July 12, 2006
Strength(s): 600MG;200MG;300MG (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Atripla. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Compositions and methods for combination antiviral therapy
Patent 8,592,397
Issued: November 26, 2013
Inventor(s): Dahl Terrence C. & Menning Mark M. & Oliyai Reza
Assignee(s): Gilead Sciences, Inc.The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one(emtricitabine, Emtriva™, (-)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.
Patent expiration dates:
- January 13, 2024✓✓
- January 13, 2024✓✓
- January 13, 2024
-
Unitary pharmaceutical dosage form
Patent 8,598,185
Issued: December 3, 2013
Inventor(s): Dahl Terrence C. & Hussain Munir A. & Lipper Robert A. & Jerzewski Robert L. & Menning Mark M. & Oliyai Reza & Yang Taiyin
Assignee(s): Bristol-Myers Squibb & Gilead Sciences, Inc.In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
Patent expiration dates:
- April 28, 2029✓
- April 28, 2029
-
Compositions and methods for combination antiviral therapy
Patent 8,716,264
Issued: May 6, 2014
Inventor(s): Dahl Terrence C. & Menning Mark M. & Oliyai Reza
Assignee(s): Gilead Sciences, Inc.The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (−)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.
Patent expiration dates:
- January 13, 2024✓✓
- January 13, 2024
-
Unitary pharmaceutical dosage form
Patent 9,018,192
Issued: April 28, 2015
Inventor(s): Dahl Terrence C. & Hussain Munir A. & Lipper Robert A. & Jerzewski Robert L. & Menning Mark M. & Oliyai Reza & Yang Taiyin
Assignee(s): Bristol-Myers Squibb & Gilead Sciences, Inc.In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component comprising tenofovir DF (and, optionally, emtricitabine) and component comprising efavirenz, wherein components and are in a stabilizing configuration. In preferred embodiments component is made by dry granulation.
Patent expiration dates:
- June 13, 2026✓
- June 13, 2026✓
- June 13, 2026
-
Compositions and methods for combination antiviral therapy
Patent 9,457,036
Issued: October 4, 2016
Inventor(s): Dahl Terrence C. & Menning Mark M. & Oliyai Reza
Assignee(s): Gilead Sciences, Inc.The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (−)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.
Patent expiration dates:
- January 13, 2024✓✓
- January 13, 2024
-
Unitary pharmaceutical dosage form
Patent 9,545,414
Issued: January 17, 2017
Inventor(s): Dahl Terrence C. & Hussain Munir A. & Lipper Robert A. & Jerzewski Robert L. & Menning Mark M. & Oliyai Reza & Yang Taiyin
Assignee(s): BRISTOL-MYERS SQUIBB & GILEAD SCIENCES, LLCIn accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
Patent expiration dates:
- June 13, 2026✓✓
- June 13, 2026✓✓
- June 13, 2026
-
Compositions and methods for combination antiviral therapy
Patent 9,744,181
Issued: August 29, 2017
Inventor(s): Dahl Terrence C. & Menning Mark M. & Oliyai Reza
Assignee(s): Gilead Sciences, Inc.The present invention relates to therapeutic combinations of [2-(6-amino-purin-9 yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S,cis)-4-amino-5-fluoro-1-(2 hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (−)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.
Patent expiration dates:
- January 13, 2024✓✓
- January 13, 2024
More about Atripla (efavirenz / emtricitabine / tenofovir disoproxil)
- Atripla consumer information
- Check interactions
- Compare alternatives
- Reviews (104)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antiviral combinations
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
